Glycogen storage disease type II
Drug research and approvals for glycogen storage disease type II: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 25 studies of glycogen storage disease type II are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 3 approved and 3 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 25
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 4
- Pompe Disease RWE Long-term Monitoring ProgramNCT07834320 · Not reported · National Taiwan University Hospital · starts Oct 1, 2023
- Phrenic Nerve and Diaphragm Electrophysiology in Pompe DiseaseNCT07664930 · Not reported · IRCCS National Neurological Institute "C. Mondino" Foundation · starts Mar 30, 2026
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset…NCT07354724 · Phase 1 / Phase 2 · Denali Therapeutics Inc. · starts May 12, 2026
- A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With…NCT07282847 · Phase 1 / Phase 2 · AskBio Inc · starts Apr 15, 2026
- Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic PathologyNCT07136844 · Not applicable · Centre Hospitalier Universitaire de Liege · starts Mar 29, 2024
- Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)NCT07123155 · Phase 2 · Shionogi · starts Oct 30, 2025
- Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment IntervalsNCT06875245 · Phase 4 · Faculty Hospital Kralovske Vinohrady · starts Mar 31, 2023
- Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle DiseasesNCT06833489 · Not applicable · Assistance Publique Hopitaux De Marseille · starts Jan 23, 2025
- Rare Glycogen Storage Diseases Natural History StudyNCT06795152 · Not reported · Duke University · starts Dec 23, 2024
Approved 4
- Alglucosidase alfaStarch hydrolytic enzyme
- Cipaglucosidase alfaGlycogen hydrolytic enzyme
- Avalglucosidase alfaGlycogen hydrolytic enzyme
- MiglustatCeramide glucosyltransferase inhibitor
Phase 3 1
Phase 2 2
- DuvoglustatLysosomal alpha-glucosidase stabiliser
- ClenbuterolBeta-2 adrenergic receptor agonist
Phase 1 or earlier 10
- AlbuterolBeta-2 adrenergic receptor agonist
- AcetaminophenCyclooxygenase inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- LidocaineSodium channel alpha subunit blocker
- RituximabB-lymphocyte antigen CD20 binding agent
- DiphenhydramineHistamine H1 receptor antagonist
- Clervonafusp alfa
- Vanglusagene ensiparvovec
- Zocaglusagene nuzaparvovec
- PyridostigmineAcetylcholinesterase inhibitor
How its trials ended
148 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 33 whose ending is known, 42% met their primary endpoint, 3% missed it and 55% stopped early.
- Completed, result not reported5235%
- Ongoing4329%
- Status unknown2014%
- Met its primary endpoint149%
- Stopped: other or unclear75%
- Stopped: sponsor or business decision64%
- Stopped: lack of efficacy21%
- Stopped: funding21%
- Missed its primary endpoint11%
- Stopped: enrollment or feasibility11%
| Aug 1, 2014 | 1. Myozyme 2. Lumizyme(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)). | Genzyme Corporation | Approved |
| May 24, 2010 | 1. Myozyme 2. LumizymeLumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac… | Genzyme Corporation | Approved |
| Apr 28, 2006 | 1. Myozyme 2. LumizymeMyozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in… | Genzyme Corporation | Approved |
| Jan 9, 2017 | ClenbuterolTreatment of Pompe disease (glycogen storage disease type II) | Avenue Therapeutics, Inc. | Designated |
| Sep 20, 2000 | Recombinant human highly phosphorylated acid…For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease) | Novazyme Pharmaceuticals, Inc. | Designated |
| Sep 10, 1996 | Human acid precursor alpha-glucosidase, recombinantTreatment of glycogen storage disease type II. | Pharming/Genzyme LLC | Designated |
| Jun 26, 2023 | OpfoldaMiglustat | Amicus Therapeutics Europe Limited | EMA ↗ |
| Mar 20, 2023 | PombilitiCipaglucosidase alfa | Amicus Therapeutics Europe Limited | EMA ↗ |
| Jun 24, 2022 | NexviadymeAvalglucosidase alfa | Sanofi B.V. | EMA ↗ |
| Mar 28, 2006 | MyozymeAlglucosidase alfa | Sanofi B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA